BioPharmSignal logoBioPharmSignal

Biotech News

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx (MGTX)MeiraGTxFinancing

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share.

Related news

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PRQRProQR Therapeutics2026-06-25 10:35 EST

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

TSHATaysha Gene Therapies2026-06-25 02:34 EST

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

IRIXIRIDEX2026-07-20 11:00 EST

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

TSHATaysha Gene Therapies2026-06-24 20:01 EST

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

View all latest news

MeiraGTx

MeiraGTx is a gene-therapy company focused on ophthalmology, rare disease, and genetics-based medicines. Its platform aims to deliver durable therapies to difficult-to-treat diseases.

Recent company news

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

Stock data

Close
12.79 USD
Market cap
855.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States